MediciNova Inc
MNOV1.355USD
-0.075-5.24%
Horário de mercado （ET）Cotações atrasadas em 15 min
66.46MValor de mercado
PerdaP/L TTM
Mais detalhes de MediciNova Inc Empresa
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Informações da empresa
Código da empresaMNOV
Nome da EmpresaMediciNova Inc
Data de listagemDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 01
Endereço4275 Executive Square
CidadeLA JOLLA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92037
Telefone18583731500
Sitehttps://medicinova.com/
Código da empresaMNOV
Data de listagemDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2024
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 23 de fev
Atualizado em: dom, 23 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Investidores
Investidores
Proporção
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Tipos de investidores
Investidores
Proporção
Investment Advisor
14.01%
Investment Advisor/Hedge Fund
3.34%
Individual Investor
2.98%
Venture Capital
2.25%
Research Firm
1.79%
Hedge Fund
0.47%
Bank and Trust
0.02%
Other
75.13%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
68
12.20M
24.87%
-484.88K
2025Q1
73
12.20M
24.88%
-318.34K
2024Q4
74
12.23M
24.94%
+65.83K
2024Q3
73
11.92M
24.31%
+15.81K
2024Q2
76
11.78M
24.02%
-90.59K
2024Q1
75
11.47M
23.39%
-882.87K
2023Q4
77
11.84M
24.14%
-895.64K
2023Q3
90
12.02M
24.50%
-1.28M
2023Q2
106
12.39M
25.26%
-1.32M
2023Q1
131
12.60M
25.68%
-2.90M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
3D Investment Partners Pte. Ltd
5.50M
11.22%
--
--
Apr 21, 2025
EW Healthcare Partners
1.11M
2.25%
--
--
Mar 31, 2025
Iwaki (Yuichi)
1.09M
2.23%
--
--
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
691.21K
1.41%
-1.45K
-0.21%
Mar 31, 2025
The Vanguard Group, Inc.
623.57K
1.27%
+241.00
+0.04%
Mar 31, 2025
Citi Investment Research (US)
591.96K
1.21%
+90.00K
+17.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
527.00K
1.07%
+12.09K
+2.35%
Mar 31, 2025
Matsuda (Kazuko)
323.00K
0.66%
--
--
Apr 21, 2025
Susquehanna International Group, LLP
250.12K
0.51%
-1.26K
-0.50%
Mar 31, 2025
UBS Financial Services, Inc.
222.20K
0.45%
-538.00
-0.24%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
